What is the APRI score?

APRI (AST-to-Platelet Ratio Index) is a non-invasive liver fibrosis scoring tool that estimates the likelihood of significant liver fibrosis or cirrhosis using two routine laboratory values: AST (normalized to the lab's upper limit of normal) and platelet count. It was developed in hepatitis C and validated broadly across chronic liver diseases.

How do I calculate the APRI score?

APRI = ((AST / AST ULN) × 100) / Platelet count (×10⁹/L). First, obtain your lab's specific upper limit of normal for AST (typically 35–40 U/L). Normalize AST by dividing by ULN. Multiply by 100. Divide by platelet count. Example: AST 60, ULN 40, Platelets 150 → APRI = ((60/40) × 100) / 150 = 150/150 = 1.0.

What are the APRI score cutoffs?

For significant fibrosis (METAVIR F2-F4): APRI 1.5 = fibrosis likely. For cirrhosis specifically: APRI 2.0 = cirrhosis likely (PPV ~89%). These cutoffs have been validated primarily in HCV and apply with somewhat lower accuracy in NAFLD.

How does APRI compare to FIB-4?

FIB-4 is generally more accurate than APRI for advanced fibrosis across liver disease etiologies, particularly NAFLD (AUROC ~0.85 vs ~0.77). FIB-4 requires four variables (age, AST, ALT, platelets) vs APRI's two (AST, platelets), making APRI simpler to calculate. AASLD/AGA 2023 recommends FIB-4 over APRI for NAFLD/MASLD; WHO 2022 recommends APRI for HCV in resource-limited settings.

How is APRI used in hepatitis C management?

WHO 2022 HCV Treatment Guidelines recommend APRI as the preferred non-invasive fibrosis staging tool in settings without FibroScan access. In HCV, APRI 1.5 indicates likely significant fibrosis. APRI >2.0 suggests cirrhosis. Pre-treatment staging guides the duration of therapy (8 vs 12 weeks) and the need for enhanced post-treatment surveillance.

How is APRI used in NAFLD/MASLD?

While APRI is validated in NAFLD, the 2023 AASLD/AGA MASLD Clinical Care Pathway recommends FIB-4 as the preferred first-line tool (higher AUROC). APRI can serve as an alternative when FIB-4 cannot be calculated, or as a supplementary assessment when FIB-4 and clinical findings are discordant. APRI indeterminate results in NAFLD should prompt FibroScan referral.

Can APRI diagnose cirrhosis?

APRI cannot diagnose cirrhosis definitively but provides strong probabilistic support. APRI >2.0 has approximately 89% positive predictive value for cirrhosis in HCV-infected patients and supports cirrhosis as the likely diagnosis, especially when combined with clinical signs (thrombocytopenia, splenomegaly, ascites) and imaging. Confirmation by FibroScan (LSM ≥15 kPa) or liver biopsy may be required for definitive staging.

What is liver fibrosis METAVIR staging?

The METAVIR scoring system stages liver fibrosis from F0 to F4: F0 = no fibrosis; F1 = portal fibrosis without septa; F2 = portal fibrosis with few septa; F3 = bridging fibrosis (numerous septa without cirrhosis); F4 = cirrhosis. APRI and FIB-4 predict METAVIR F2-F4 (significant fibrosis). METAVIR staging is determined histologically by liver biopsy and is the gold standard against which non-invasive tests are calibrated.

When should a liver biopsy be performed?

Liver biopsy is indicated when: non-invasive tests (APRI, FIB-4, FibroScan) give discordant or indeterminate results; clinical decisions require definitive fibrosis staging (e.g., treatment eligibility, trial enrollment); monitoring treatment response in research settings; or when an alternative diagnosis cannot be excluded non-invasively (e.g., autoimmune hepatitis vs NAFLD vs overlap syndrome). Biopsy carries 0.01% mortality and approximately 0.5% major complication rate.

How is APRI used in hepatitis B management?

APRI is validated for hepatitis B fibrosis staging, with similar cutoffs as HCV (APRI >1.5 for significant fibrosis, >2.0 for cirrhosis). In HBV, APRI helps guide treatment initiation decisions in resource-limited settings where HBV DNA testing or FibroScan is unavailable. Serial APRI monitoring during antiviral therapy (entecavir, tenofovir) tracks fibrosis regression as a treatment response marker.

What are the main limitations of APRI?

Key limitations: (1) Thrombocytopenia from non-hepatic causes (ITP, chemotherapy) inflates APRI. (2) Acute hepatitis flares transiently elevate AST and APRI. (3) AST ULN varies by laboratory — using the wrong value changes results. (4) Lower accuracy for NAFLD fibrosis than FIB-4 (AUROC ~0.77 vs ~0.85). (5) Large indeterminate zone requiring additional testing. (6) Cannot determine fibrosis etiology.

What does it mean to get a FibroScan for liver disease?

FibroScan (vibration-controlled transient elastography, VCTE) is a non-invasive ultrasound-based device that measures liver stiffness in kilopascals (kPa) as a surrogate for fibrosis. Normal liver stiffness is <5 kPa; stiffness ≥8 kPa suggests significant fibrosis; ≥15 kPa suggests cirrhosis. FibroScan takes about 10 minutes, is painless, and is the recommended second-line test when APRI or FIB-4 fall in the indeterminate zone.

Online Medical Tools — APRI Score

Printed on 9/2/2026

For informational purposes only. This is not medical advice.

Gastroenterology

APRI Score

APRI is a non-invasive fibrosis marker that combines AST elevation relative to lab ULN and thrombocytopenia signal from platelet count. It is commonly used in chronic hepatitis and broader fibrosis triage pathways.

Formula: APRI = ((AST / AST ULN) x 100) / Platelets

AST

U/L

AST Upper Limit of Normal

U/L

Platelet Count

x10^9/L

Save your results with a free account

Keep a history of calculations, favorite tools, and access your dashboard anytime.

Create free account Sign in

How It Works

Gather three inputs: AST level, AST upper limit of normal, and platelet count

APRI requires three values from routine laboratory testing: AST (U/L) from the liver function panel, the upper limit of normal (ULN) for AST established by your specific laboratory (typically 35–40 U/L for most labs, but verify your lab's reference range), and platelet count (×10⁹/L or k/µL) from the complete blood count. Using your lab's specific ULN is important — do not use a fixed default value, as AST ULN varies by analyzer and population.

Calculate APRI using the validated formula

APRI = ((AST ÷ AST ULN) × 100) ÷ Platelet count. First, normalize AST by dividing by the lab's ULN, then multiply by 100, then divide by the platelet count in ×10⁹/L. Example: AST 80 U/L, ULN 40 U/L, platelets 120 ×10⁹/L — APRI = ((80/40) × 100) / 120 = 200 / 120 = 1.67. This indicates likely significant fibrosis. The formula was designed to be simple enough for calculation without a dedicated tool.

Interpret APRI using validated cutoffs for fibrosis and cirrhosis

Fibrosis cutoffs (METAVIR F2-F4): APRI <0.5 = significant fibrosis unlikely (NPV ~80%); APRI 0.5–1.5 = indeterminate (requires second-line testing such as FibroScan); APRI >1.5 = significant fibrosis likely (PPV ~85%). Cirrhosis cutoffs: APRI <1.0 = cirrhosis unlikely (NPV ~92%); APRI >2.0 = cirrhosis likely (PPV ~89%). In resource-limited settings, APRI >2.0 in an HCV-infected patient with clinical signs of portal hypertension provides strong indirect evidence of cirrhosis.

Who Uses the APRI Score

Hepatitis C Fibrosis Staging in Resource-Limited Settings

Infectious disease physicians, WHO-implementing clinicians

WHO 2022 HCV Treatment Guidelines recommend APRI as the preferred non-invasive fibrosis test when FibroScan is unavailable. APRI requires only a basic metabolic panel and CBC — equipment available at virtually any clinic globally — making it the dominant fibrosis staging tool in global HCV elimination programs.

NAFLD Fibrosis Staging as Second-Line After FIB-4

Hepatologists and gastroenterologists

While AASLD/AGA 2023 recommends FIB-4 as the first-line tool for NAFLD/MASLD, APRI serves as a valid alternative when FIB-4 is unavailable or as a complementary assessment. Combined FIB-4 + APRI concordance improves specificity for advanced fibrosis.

Hepatitis B Progression Monitoring

Hepatologists

APRI has been validated for HBV fibrosis staging in multiple Asian and African cohorts. Serial APRI monitoring in chronic HBV patients on antiviral therapy tracks fibrosis regression (falling APRI over time with effective viral suppression).

Evaluating Cirrhosis Risk Without FibroScan

General practitioners in community settings

In practices without access to elastography or hepatology referral, APRI >2.0 with clinical signs (splenomegaly, thrombocytopenia, ascites) provides a clinically actionable estimate of cirrhosis that can guide urgent referral.

WHO-Recommended Tool for Global HCV Fibrosis Staging

Global health clinicians and program managers

APRI is specifically endorsed in the 2022 WHO Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection as the non-invasive staging tool of choice in settings without FibroScan access, making it the world's most widely implemented fibrosis staging method by patient volume.

Pro Tips

APRI is simpler than FIB-4 but less accurate for NAFLD

APRI uses only two variables (AST and platelets) vs FIB-4's four (age, AST, ALT, platelets). This simplicity makes it faster to calculate manually and more accessible globally. However, for NAFLD/MASLD specifically, FIB-4 has higher AUROC (~0.85 vs ~0.77 for APRI) and is preferred by AASLD/AGA 2023.

WHO 2022 HCV guidelines recommend APRI globally for resource-limited settings

The WHO 2022 HCV guidelines specifically recommend APRI (over FIB-4 or other tools) for HCV fibrosis staging where FibroScan is unavailable — the primary consideration being accessibility and cost. In high-income settings with FibroScan access, APRI has largely been superseded by FIB-4 and elastography.

APRI is less accurate for NAFLD fibrosis than FIB-4

Multiple systematic reviews and meta-analyses comparing APRI and FIB-4 in NAFLD cohorts consistently show FIB-4 has superior AUROC. Lin et al. (Ann Intern Med 2011) confirmed APRI AUROC ~0.77 for significant fibrosis in HCV, with lower performance in NAFLD (~0.73). Use APRI in NAFLD only when FIB-4 cannot be calculated.

Always use your laboratory's specific AST ULN — not a default value

AST ULN varies by laboratory analyzer, population, and institutional standards (typically 35–45 U/L). Using a wrong ULN directly affects the APRI value proportionally. In many electronic calculators, the default ULN is set to 40 U/L — verify this matches your lab before interpreting results in clinical decisions.

Thrombocytopenia from any cause inflates APRI artificially

Like FIB-4, APRI divides by platelet count, so immune thrombocytopenia (ITP), drug-induced thrombocytopenia, chemotherapy-related bone marrow suppression, or hypersplenism from portal hypertension all inflate APRI independent of fibrosis severity. In thrombocytopenic patients with non-hepatic causes, use elastography instead.

Acute hepatitis flares transiently elevate APRI — do not score during flares

AST elevation during acute hepatitis A, B, or C flares, or drug-induced liver injury, will transiently drive APRI into the high-risk zone even in patients without significant fibrosis. Calculate APRI only when transaminases are at the patient's chronic stable baseline, typically 4–8 weeks after resolution of an acute injury.

Combined FIB-4 + APRI improves diagnostic accuracy

When both scores concordantly indicate high fibrosis risk (FIB-4 >2.67 AND APRI >1.5), the likelihood of true advanced fibrosis is higher than either test alone. Concordant low results (FIB-4 <1.30 AND APRI <0.5) have high negative predictive value. Discordant results (one high, one low) represent a gray zone requiring second-line testing.

APRI has been validated for hepatitis B fibrosis staging

Multiple studies in chronic HBV cohorts, predominantly in Asia and Africa where HBV burden is highest, have validated APRI for fibrosis staging with performance similar to HCV settings. Serial APRI in HBV patients on entecavir or tenofovir therapy shows APRI decline as fibrosis regresses, providing a practical monitoring tool in low-resource contexts.

Common Questions About Your Results

No. APRI requires stable chronic AST values to provide meaningful fibrosis estimates. An acute hepatitis flare (viral, drug-induced, ischemic) transiently elevates AST and will produce a falsely high APRI suggesting significant fibrosis even in a patient without meaningful chronic liver disease. Wait until AST returns to the chronic stable baseline (typically 4–8 weeks after acute injury resolution) before using APRI for fibrosis staging.

In this case, APRI is unreliable as a fibrosis marker. Platelet count is the denominator of APRI, so any non-hepatic cause of thrombocytopenia (ITP, drug-induced, bone marrow suppression) mathematically inflates APRI to values suggesting advanced fibrosis even in a healthy liver. Use vibration-controlled transient elastography (FibroScan/VCTE) as an alternative — it measures liver stiffness directly and is not affected by platelet count.

APRI 0.5–1.5 is the indeterminate zone for significant fibrosis — neither ruling in nor ruling out advanced fibrosis. The recommended next step per current guidelines is vibration-controlled transient elastography (FibroScan/VCTE). If unavailable, FIB-4 >2.67 combined with clinical features (low albumin, thrombocytopenia, splenomegaly) strengthens the case for hepatology referral. Liver biopsy remains the gold standard when non-invasive testing is inconclusive and clinical decisions depend on fibrosis staging.

Evidence-Based Methodology

APRI was developed by Wai et al. (Hepatology 2003) in 270 HCV patients. A systematic review by Lin et al. (Ann Intern Med 2011) across 40 studies found AUROC 0.77 for significant fibrosis and 0.83 for cirrhosis in HCV. WHO 2022 HCV Treatment Guidelines recommend APRI as the preferred non-invasive fibrosis test in resource-limited settings. AASLD/AGA 2023 MASLD Pathway recommends FIB-4 as the preferred first-line tool over APRI for NAFLD.

Clinical Content Trust

Last reviewed:: April 21, 2026
Guideline version:: General evidence framework v2026.04
Source set version:: Primary-source set v1

How to Interpret Your Result

Higher APRI values generally indicate greater fibrosis likelihood, while lower values suggest lower probability of advanced fibrosis.

When to Use This Tool

Use APRI for non-invasive fibrosis risk stratification when AST and platelets are available, especially in initial hepatology triage.

Limitations

APRI can be distorted by acute hepatitis flares, lab-specific AST ULN definitions, and non-hepatic causes of thrombocytopenia.

Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.

Changelog

April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.

Related Tools